Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Atopic eczema

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    266 result(s) found for: Atopic eczema. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-004432-20 Sponsor Protocol Number: ACE-ATOPI-1 Start Date*: 2008-09-03
    Sponsor Name:ACE Aps
    Full Title: Efficacy and tolerability of captopril oinment 0,1% og 0,3% in atopic dermatitis. A randomised, double-blind, placebocontrolled, doseescalating, intra-individual clinical study.
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006982-17 Sponsor Protocol Number: 05.09.2006 Start Date*: 2007-07-12
    Sponsor Name:Division of Special and Environmental Dermatology
    Full Title: UVA 1 therapy versus 5-MOP UVA photochemotherapy for patients with severe generalized atopic dermatitis
    Medical condition: Severe generalized atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004443-22 Sponsor Protocol Number: Spirig I 04-05 Start Date*: Information not available in EudraCT
    Sponsor Name:Spirig Pharma AG
    Full Title: Untersuchung der Wirksamkeit einer glycerinhaltigen Creme bei der Behandlung von Atopischer Dermatitis. Kontrolliert, randomisierte Doppel-Blind-Studie.
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10012438
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002926-23 Sponsor Protocol Number: RV2478B 03 LT 301 100 MVC Start Date*: 2004-12-22
    Sponsor Name:INSTITUT DE RECHERCHE PIERRE FABRE
    Full Title: Evaluation of the impact of the moisturizing milk RV2478B on the use of corticoids and on quality of life, in a population of children with atopic dermatitis.
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    6.1 10012438 PT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003485-25 Sponsor Protocol Number: V00034 CR 402 1B Start Date*: 2008-10-01
    Sponsor Name:Pierre Fabre Médicament
    Full Title: Impact of the V0034CR 01B emollient on atopic dermatitis symptoms in children. A randomised, placebo-controlled, parallel-groups, double-blind study
    Medical condition: Children between 2 and 7 years, presenting with atopic dermatitis according to the diagnostic criteria of the UK Working party and whose IGA score is < or = 1 at inclusion.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003639 Atopic dermatitis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) FR (Completed) EE (Completed) DE (Completed) PL (Completed) LV (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021284-33 Sponsor Protocol Number: protocoltwo17.12.09. Start Date*: 2010-10-07
    Sponsor Name:Research and Development Department, John Radcliffe Hospital
    Full Title: Proof of concept study of combined allergen immunotherapy and antibiotics for the treatment of chronic atopic eczema
    Medical condition: Severe chronic atopic eczema
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012435 Dermatitis and eczema HLT
    12.1 10001712 Allergic eczema LLT
    12.1 10003641 Atopic eczema LLT
    12.1 10012454 Dermatitis eczematoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011931-11 Sponsor Protocol Number: H 552 000 - 0911 Start Date*: Information not available in EudraCT
    Sponsor Name:Almirall Hermal GmbH
    Full Title: Explorative, double-blind, randomized, controlled multi-center phase II study to evaluate the efficacy and safety of topically applied combinational product LAS41003 once daily versus corresponding...
    Medical condition: Patients aged 18 and older suffering from at least one clinically diagnosed superinfected or impetiginised eczema such as e.g. • superinfected or impetiginised atopic eczema • superinfected or impe...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10021773 Infected eczema LLT
    12.0 10014184 Eczema LLT
    12.0 10014188 Eczema allergic LLT
    12.0 10014191 Eczema atopic LLT
    12.0 10014199 Eczema infected LLT
    12.0 10014201 Eczema nummular LLT
    12.0 10051890 Eczema impetiginous LLT
    12.0 10000618 Actinic reticuloid-photosensitive eczema LLT
    12.0 10001712 Allergic eczema LLT
    12.0 10003641 Atopic eczema LLT
    12.0 10010803 Contact eczema LLT
    12.0 10014206 Eczematous dermatitis LLT
    12.0 10021773 Infected eczema LLT
    12.0 10049706 Eczematous dermatitis infected LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003406-31 Sponsor Protocol Number: CCMK389B12201 Start Date*: 2021-01-10
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, subject and investigator blinded, placebo-controlled multicenter study to assess the efficacy and safety of CMK389 in patients with moderate to severe atopic dermatitis
    Medical condition: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) FR (Completed) CZ (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003725-17 Sponsor Protocol Number: D2213C00001 Start Date*: 2015-04-15
    Sponsor Name:MedImmune
    Full Title: A Phase 2b, Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Tralokinumab in Adult Subjects with Moderate-to-Severe Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001472-20 Sponsor Protocol Number: LEO19123-C21 Start Date*: 2006-08-15
    Sponsor Name:LEO Pharma A/S
    Full Title: LEO19123 Cream in the Treatment of Atopic Dermatitis A Phase II, proof of concept study, testing once daily use of two dose-combinations of LEO19123 cream (calcipotriol and LEO80122) in the treatm...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed) FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003667-31 Sponsor Protocol Number: TUD_PROVE_001 Start Date*: 2007-03-30
    Sponsor Name:Medical Faculty, TU Dresden
    Full Title: Prednisolone vs. Ciclosporine in Severe Atopic Eczema. PROVE - Study
    Medical condition: atopic eczema
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003641 Atopic eczema LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000946-37 Sponsor Protocol Number: R668-AD-1121 Start Date*: 2012-06-13
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A randomized, double-blind, parallel-group, placebo-controlled study to assess the safety of REGN668 administered concomitantly with topical corticosteroids to patients with moderate-to-severe Atop...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001227-12 Sponsor Protocol Number: M19-850 Start Date*: 2020-03-13
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3b, open label treatment extension study of upadacitinib for the treatment of adult subjects with moderate to severe atopic dermatitis who successfully completed treatment in the M16-046 study
    Medical condition: Moderate to severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) FI (Completed) HU (Completed) CZ (Completed) ES (Ongoing) NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) HR (Completed) IT (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2004-002099-40 Sponsor Protocol Number: 308962 Start Date*: 2005-01-20
    Sponsor Name:Schering AG
    Full Title: Double-blind, randomized, reference-controlled, multicenter, parallel-group study to compare the efficacy and safety of Advantan ointment once daily with Protopic 0.03% ointment twice daily over ma...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10012438 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-007323-64 Sponsor Protocol Number: P441201CD Start Date*: 2009-02-09
    Sponsor Name:Serentis Limited
    Full Title: A phase II, double-blind, vehicle controlled study to determine the efficacy, safety and toleration of SRD441 ointment in patients with atopic dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002477-23 Sponsor Protocol Number: FG-506-06-FR-04 Start Date*: 2005-04-01
    Sponsor Name:Fujisawa GmbH
    Full Title: Comparative, multicentre, randomised, double-blind study to assess the efficacy of tacrolimus 0.1% ointment versus fluticasone 0.005% ointment in adult patients suffering from moderate to severe at...
    Medical condition: Moderate to severe atopic dermatitis and presenting with so-called "red face" lesions of the head and neck.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10003639 LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002673-22 Sponsor Protocol Number: 309189 Start Date*: 2005-03-11
    Sponsor Name:Schering AG
    Full Title: Double-blind, placebo controlled, randomized, multicenter, parallel-group study to compare the efficacy and safety of Advantan cream twice weekly with Advabas cream during a maintenance phase of 16...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10012438 PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-002133-36 Sponsor Protocol Number: 1401920 Start Date*: Information not available in EudraCT
    Sponsor Name:INTENDIS GmbH
    Full Title: A multicenter, randomized, double-blind clinical study to examine the efficacy and safety of Zarzenda® in comparison to Elidel® in the management of mild to moderate atopic dermatitis in children a...
    Medical condition: Mild to moderate atopic dermatitis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003639 Atopic dermatitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-003066-34 Sponsor Protocol Number: 101-PG-PSC-150 Start Date*: 2007-01-23
    Sponsor Name:LETI Pharma GmbH
    Full Title: A randomized, double blinded, placebo controlled multicenter study for the efficacy and safety of Depigoid® House dust mites (HDM) in patients suf-fering from moderate to severe atopic eczema.
    Medical condition: Moderate to severe atopic eczema with or without rhinitis and/or rhinoconjunctivitis caused by clinical relevant IgE-mediated sensitization against House dust mites (HDM) leading to aggravation of ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003641 Atopic eczema LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-001528-14 Sponsor Protocol Number: 67484703ADM2001 Start Date*: 2023-04-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2a, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-67484703 in Participants with Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 21:33:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA